Carbon-Carbon bond cleavage in activation of the prodrug nabumetone

Drug Metabolism and Disposition

Volumn 42, Issue 5, 2014, Pages 828-838

  Varfaj, Fatbardha ^a   Zulkifli, Siti N A ^b,c   Park, Hyoung Goo ^a   Challinor, Victoria L ^b   De Voss, James J ^b   De Montellano, Paul R Ortiz ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; ALCOHOL DERIVATIVE; ALDEHYDE DERIVATIVE; ANION; CYTOCHROME P450; CYTOCHROME P450 1A2; FERRIC PEROXO ANION; KETONE DERIVATIVE; NABUMETONE; NABUMETONE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; 6-METHOXY-2-NAPHTHYLACETIC ACID; ALKANONE; ARYLACETIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYP1A2 PROTEIN, HUMAN;

ARTICLE; CARBON CARBON BOND CLEAVAGE; CATALYSIS; CHEMICAL REACTION; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVATION; HYDROXYLATION; OXIDATION; PRIORITY JOURNAL; BIOCATALYSIS; BIOTRANSFORMATION; ENZYME SPECIFICITY; ENZYMOLOGY; ESCHERICHIA COLI; GENETIC TRANSFECTION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; METABOLISM; MICROSOME; OXIDATION REDUCTION REACTION;

BIOCATALYSIS; BIOTRANSFORMATION; BUTANONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 CYP1A2; ESCHERICHIA COLI; HUMANS; IN VITRO TECHNIQUES; MICROSOMES; NAPHTHALENEACETIC ACIDS; OXIDATION-REDUCTION; PRODRUGS; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 84898823724     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.056903     Document Type: Article

References (33)

1. Akhtar M, Wright JN, and Lee-Robichaud P (2011) A review of mechanistic studies on aromatase (CYP19) and 17a-hydroxylase-17,20-lyase (CYP17). J Steroid Biochem Mol Biol 125:2-12.
2. Berry EA and Trumpower BL (1987) Simultaneous determination of hemes a, b, and c from pyridine hemochrome spectra. Anal Biochem 161:1-15.
3. Cho US, Park EY, Dong MS, Park BS, Kim K, and Kim KH (2003) Tight-binding inhibition by alpha-naphthoflavone of human cytochrome P450 1A2. Biochim Biophys Acta 1648:195-202.
4. Dale JA and Mosher HS (1973) Nuclear magnetic resonance enantiomer regents. Configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, O-methylmandelate, and alpha-methoxy-alpha- trifluoromethylphenylacetate (MTPA) esters. J Am Chem Soc 95:512-519.
5. Goudie AC (1983) inventors, Beecham Group L, assignee. Naphthalene derivatives, a process for their preparation and their use in anti-inflammatory pharmaceutical compositions. U.S. patent 4382959 A. 10 May 1983.
6. Goudie AC, Gaster LM, Lake AW, Rose CJ, Freeman PC, Hughes BO, and Miller D (1978) 4-(6-Methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of antiinflammatory compounds. J Med Chem 21:1260-1264.
7. Guengerich FP, Martin MV, Sohl CD, and Cheng Q (2009) Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nat Protoc 4:1245-1251.
8. Haddock RE, Jeffery DJ, Lloyd JA, and Thawley AR (1984) Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 14:327-337.
9. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, and Ekbom A (2004) Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64:2315-2343; discussion 2344-2315.
10. Jacques J and Horeau A (1948) Structure moleculaire et activité oestrogene (VI). Preparation de quelques dérivés de l'acide amphihydroxynaphtyl b-propionique (acide allenolique). Bull Soc Chim Fr 15:711-716.
11. Kelly DR (1999) A new method for the determination of the absolute stereochemistry of aromatic and heteroaromatic alkanols using Mosher's esters. Tetrahedron Asymmetry 10:2927-2934.
12. Kim DH, Kim KH, Isin EM, Guengerich FP, Chae HZ, Ahn T, and Yun CH (2008) Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli. Protein Expr Purif 57:188-200.
13. Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP, 3rd, Freiwald S, Zientek M, and Totah RA (2010) Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347-356.
14. Mangan FR, Flack JD, and Jackson D (1987) Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. Am J Med 83 (4B):6-10.
15. Matsumoto K, Nemoto E, Hasegawa T, Akimoto M, and Sugibayashi K (2011) In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull 34: 734-739.
16. Messina A, Nencioni S, Gervasi PG, Gotlinger KH, Schwartzman ML, and Longo V (2010) Molecular cloning and enzymatic characterization of sheep CYP2J. Xenobiotica 40:109-118.
17. Nishida CR, Lee M, and de Montellano PR (2010) Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78:497-502.
18. Nobilis M, Mikusek J, Szotáková B, Jirásko R, Holcapek M, Chamseddin C, Jira T, Kucera R, Kunes J, and Pour M (2013) Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites. J Pharm Biomed Anal 80:164-172.
19. Ortiz de Montellano PR (2005) Cytochrome P450 Structure, Mechanism, and Biochemistry. KluwerAcademic/Plenum Publishers, New York
20. Pataki J, Di Raddo P, and Harvey RG (1989) An efficient synthesis of the highly tumorigenic anti-diol epoxide derivative of benzo[c]phenanthrene. J Org Chem 54:840-844.
21. Patel BN, Sharma N, Sanyal M, Prasad A, and Shrivastav PS (2008) High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. Biomed Chromatogr 22:1213-1224.
22. Porubsky PR, Meneely KM, and Scott EE (2008) Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J Biol Chem 283:33698-33707.
23. Schmidt JM, Tremblay GB, Plastina MA, Ma F, Bhal neé Basra S, Feher M, Dunn-Dufault R, and Redden PR (2005) In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor. Bioorg Med Chem 13:1819-1828.
24. Singh R, Ting JG, Pan Y, Teh LK, Ismail R, and Ong CE (2008) Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23:165-174.
25. Skarydova L, Nobilis M, and Wsól V (2013) Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro. Xenobiotica 43:346-354.
26. Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, and Zanger UM (2009) A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 37: 1017-1024.
27. VanRheenen V, Kelly RC, and Cha DY (1976) Improved catalytic OsO4 oxidation of olefins to cis-1,2-glycols using tertiary amine oxides as oxidant. Tetrahedron Lett 17:1973-1976.
28. Varfaj F, Lampe JN, and Ortiz de Montellano PR (2012) Role of cysteine residues in heme binding to human heme oxygenase-2 elucidated by two-dimensional NMR spectroscopy. J Biol Chem 287:35181-35191.
29. Viviano M, Glasnov TN, Reichart B, Tekautz G, and Kappe CO (2011) A scalable two-step continuous flow synthesis of nabumetone and related 4-aryl-2-butanones. Org Process Res Dev 15:858-870.
30. Wang X, Medzihradszky KF, Maltby D, and Correia MA (2001) Phosphorylation of native and heme-modified CYP3A4 by protein kinase C: a mass spectrometric characterization of the phosphorylated peptides. Biochemistry 40:11318-11326.
31. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630-35637.
32. Wu ZL, Sohl CD, Shimada T, and Guengerich FP (2006) Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 69:2007-2014.
33. Yun CH, Miller GP, and Guengerich FP (2000) Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 39:11319-11329.